Reduced ADAMTS13 Activity in Correlation with Pathophysiology, Severity, and Outcome of COVID-19: A Retrospective Observational Study

• Published in: International journal of infectious diseases Vol. 117; pp. 334 - 344
• Main Authors: Hafez, Wael, Ziade, Mohamad Azzam, Arya, Arun, Saleh, Husam, Ali, Sara, Rao, Srinivasa Raghu, Fdl Alla, Osman, Ali, Mohamed, Zouhbi, Mouhamad Al, Abdelrahman, Ahmed
• Format: Journal Article
• Language: English
• Published: Canada Elsevier Ltd 01.04.2022; The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases; Elsevier
• Subjects: ADAMTS13; Anticoagulants - therapeutic use; Anticoagulation; COVID-19; Cytokine storm; Humans; Pneumonia; Respiration, Artificial; Retrospective Studies; SARS-CoV-2; Thrombosis; Pneumonia; WPBs; CAC; VWF; TMA; Anticoagulation; Thrombosis; Cytokine storm; COVID-19; SARS-CoV-2; ADAMTS13; UAE; rADAMTS13
• ISSN: 1201-9712; 1878-3511
• DOI: 10.1016/j.ijid.2022.02.019

•Coagulopathy risk and microthrombosis were noticed in patients with COVID-19•ADAMTS13 and the VWF/ADAMTS13 axis could be connected to this risk•Low ADAMTS13 was linked to pneumonia, COVID-19 severity, and ventilation need•Recombinant ADAMTS13 could be a novel therapeutic strategy for Severe COVID-19 Low ADAMTS13 activity has been suggested to be an interplaying factor in the pathogenesis of COVID-19, considering that it is a thromboinflammatory disease with high risk of microthrombosis. The study aimed to explore the correlation between ADAMTS13 activity and the pathophysiological pathway of COVID-19. We carried out a retrospective observational study of 87 patients with COVID-19 in NMC Royal Hospital, Abu Dhabi, UAE. ADAMTS13 activity was measured and compared with patients’ characteristics and clinical outcomes. Low ADAMTS13 activity was associated with pneumonia (p = 0.007), severity of COVID-19 (p <0.001), and mechanical ventilation rates (p = 0.018). Death was more frequently observed among patients (5 patients) with low ADAMTS13 activity compared with normal activity (1 patient), as well as inflammatory markers. Decreased ADAMTS13 activity increased with the risk of pneumonia, severity of COVID-19, need for mechanical ventilation, and use of anticoagulants ([OR = 4.75, 95% CI 1.54–18.02, p = 0.011], [OR = 6.50, 95% CI 2.57–17.74; p <0.001], [OR = 4.10, 95% CI 1.29–15.82; p = 0.024], [OR = 8.00, 95% CI 3.13–22.16; p <0.001], respectively). The low ADAMTS13 activity group had a slightly longer time to viral clearance than the normal ADAMTS13 activity group, but it was not statistically significant (20 days, 95% CI 16–27 days vs 17 days, 95% CI 13–22 days; p = 0.08; Log rank = 3.1). Low ADAMTS13 activity has been linked to pneumonia, COVID-19 severity, use of anticoagulants, and need for mechanical ventilation but not to mortality. We propose rADAMTS13 as a novel treatment for severe COVID-19.